The risk of developing liver cancer may be increased by excessive body fat and decreased by coffee consumption.
Stephen Hursting, PhD, MPH
The risk of developing liver cancer may be increased by excessive body fat and decreased by coffee consumption, according to an ongoing systematic review conducted in collaboration with the American Institute of Cancer Research.
The large international study analyzed data from 34 studies involving 8.2 million individuals, with over 24,500 liver cancer diagnoses. The World Cancer Research Fund International’s Continuous Update Project (CUP) completed the study.
In addition to new connections between coffee intake and weight, the report strengthened the association between alcohol and liver cancer. Taken together, the researchers estimated that maintaining a healthy weight and avoiding alcohol consumption could prevent 30% of new liver cancer cases (nearly 10,700 in 2015).
"This is the first time there's been such a clear signal from a rigorous systematic review on the links between obesity increasing risk of liver cancer and coffee decreasing risk," Stephen Hursting, PhD, MPH, researcher at the University of North Carolina Chapel Hill and one of the CUP expert panelists, said in a statement.
The reduction in risk seen with coffee consumption adds to a 2013 report connecting coffee with endometrial cancer prevention. Further research is examining whether coffee contains anti-cancer components. "[Coffee] may act on liver enzymes that eliminate carcinogens, for example," Hursting speculated.
Obesity has been associated with a variety of cancer types, including breast cancer. Research suggests that inflammation caused by obesity could be a leading cause for the increase in cancer. In general, a high fat diet and a BMI over 30 leads to increased proinflammatory mediators.
"The evidence on obesity and cancer is only getting stronger," said Hursting. "We're looking at a tsunami of obesity-related cancer coming. People really need to be aware of this issue and we need more research on weight loss strategies and understanding the mechanisms so that we can break this connection."
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More